- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Crossmark names Janet Carter-Smith VP
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Teva launches generic drug for cystic fibrosis patients
- Roxane Labs' generic prostate drug gets tentative approval from FDA
NORTH WALES, Pa. Teva Pharmaceuticals has launched a drug for treating migraine headaches, the generic drug maker said.
Teva announced the launch of naratriptan tablets in the 1 mg and 2.5-mg strengths. The tablets are a generic version of GlaxoSmithKline’s Amerge. The drug is used to treat acute migraine attacks in adults with or without visual disturbances preceding the attacks known as aura.
Amerge had sales of $59.6 million during the 12-month period ending in April, according to IMS Health. Sandoz and Roxane Labs, the respective generics divisions of Swiss drug maker Novartis and German drug maker Boehringer Ingelheim, have launched genericw versions of Amerge as well.